shockwave
coronary
ivl
pivotal
study
results
presented
session
tct
connect
santa
clara
globe
newswire
shockwave
medical
nasdaq
swav
pioneer
development
commercialization
intravascular
lithotripsy
ivl
treat
severely
calcified
cardiovascular
disease
announced
today
pivotal
results
disrupt
cad
iii
study
accepted
presentation
clinical
science
session
tct
connect
investigational
device
exemption
ide
study
first
study
powered
evaluate
safety
effectiveness
coronary
ivl
treatment
severely
calcified
coronary
arteries
delighted
cad
iii
data
featured
part
session
tct
connect
said
keith
dawkins
chief
medical
officer
shockwave
medical
behalf
entire
shockwave
team
want
thank
investigators
research
coordinators
patients
supported
study
start
whose
enthusiasm
perseverance
even
amid
covid
got
us
point
today
completing
cad
iii
study
represents
significant
milestone
shockwave
look
forward
results
shared
investigators
tct
addition
primary
endpoint
analysis
tct
connect
accepted
post
data
prospective
optical
coherence
tomography
oct
patients
within
cad
iii
cohort
authored
richard
shlofmitz
facc
chairman
cardiology
francis
hospital
heart
center
details
session
follows
presentation
title
disrupt
cad
iii
safety
effectiveness
intravascular
lithotripsy
treatment
severe
coronary
calcification
time
october
pm
eastern
time
presenter
dean
kereiakes
facc
fscai
medical
director
christ
hospital
heart
vascular
center
christ
hospital
research
institute
professor
clinical
medicine
ohio
state
university
investigator
disrupt
cad
iii
shockwave
hosting
event
analysts
institutional
investors
eastern
time
thursday
october
session
webcast
event
include
remarks
dean
kereiakes
well
interactive
question
answer
session
panel
experts
interested
parties
may
access
live
audio
webcast
presentation
visiting
investors
section
shockwave
website
https
replay
webcast
available
following
presentation
shockwave
coronary
ivl
catheters
commercially
available
treatment
de
novo
coronary
artery
disease
europe
select
geographies
limited
investigational
use
united
states
disrupt
cad
iii
disrupt
cad
iii
prospective
multicenter
global
ide
study
designed
demonstrate
safety
effectiveness
shockwave
coronary
ivl
system
shockwave
coronary
ivl
catheter
de
novo
calcified
stenotic
coronary
arteries
prior
stenting
study
enrolled
patients
exceeding
minimum
requirement
patients
per
priori
statistical
plan
agreed
fda
patients
enrolled
sites
united
states
france
germany
united
kingdom
patients
followed
two
years
study
assessing
freedom
major
adverse
cardiac
events
mace
within
days
index
procedure
primary
safety
endpoint
primary
effectiveness
endpoint
procedural
success
defined
stent
delivery
residual
stenosis
less
percent
without
mace
investigators
study
dean
kereiakes
jonathan
hill
consultant
cardiologist
royal
brompton
hospital
london
shockwave
medical
shockwave
focused
developing
commercializing
products
intended
transform
way
calcified
cardiovascular
disease
treated
shockwave
aims
establish
new
standard
care
interventional
treatment
atherosclerotic
cardiovascular
disease
differentiated
proprietary
local
delivery
sonic
pressure
waves
treatment
calcified
plaque
company
refers
intravascular
lithotripsy
ivl
ivl
minimally
invasive
safe
way
significantly
improve
patient
outcomes
view
animation
ivl
procedure
information
visit
statements
press
release
contains
statements
relating
shockwave
expectations
projections
beliefs
prospects
including
statements
regarding
shockwave
product
development
outlook
statements
within
meaning
federal
securities
laws
nature
uncertain
words
believe
may
estimate
continue
anticipate
intend
expect
plans
similar
expressions
intended
identify
statements
statements
guarantees
future
performance
cautioned
place
undue
reliance
statements
business
operations
subject
variety
risks
uncertainties
consequently
actual
results
may
differ
materially
projected
statements
factors
could
cause
actual
results
differ
projected
include
limited
impact
pandemic
operations
financial
results
liquidity
capital
resources
including
sales
expenses
supply
chain
manufacturing
research
development
activities
clinical
trials
employees
ability
design
develop
manufacture
market
innovative
products
treat
patients
challenging
medical
conditions
particularly
peripheral
artery
disease
coronary
artery
disease
aortic
stenosis
expected
future
growth
including
growth
international
sales
size
growth
potential
markets
products
ability
serve
markets
rate
degree
market
acceptance
products
coverage
reimbursement
procedures
performed
using
products
performance
third
parties
connection
development
products
including
suppliers
regulatory
developments
united
states
foreign
countries
ability
obtain
maintain
regulatory
approval
clearance
products
expected
timelines
plans
research
develop
commercialize
products
approved
cleared
product
ability
scale
organizational
culture
cooperative
product
development
commercial
execution
development
regulatory
approval
efficacy
commercialization
competing
products
loss
key
scientific
management
personnel
expectations
regarding
period
qualify
emerging
growth
company
jobs
act
ability
develop
maintain
corporate
infrastructure
including
internal
controls
financial
performance
capital
requirements
expectations
regarding
ability
obtain
maintain
intellectual
property
protection
products
well
ability
operate
business
without
infringing
intellectual
property
rights
others
risks
uncertainties
well
others
discussed
greater
detail
filings
securities
exchange
commission
sec
including
part
item
ia
risk
factors
recent
annual
report
form
filed
sec
periodic
reports
filed
sec
may
additional
risks
presently
aware
currently
believe
immaterial
could
adverse
impact
business
statements
based
current
expectations
estimates
assumptions
regarding
future
events
applicable
dates
statements
make
commitment
revise
update
statements
order
reflect
events
circumstances
may
change
media
contact
scott
shadiow
sshadiow
investor
contact
debbie
kaster
dkaster
